Egetis Therapeutics Logo

Egetis Therapeutics

Develops and commercializes drugs for serious rare diseases with unmet medical needs.

EGTX | ST

Overview

Corporate Details

ISIN(s):
SE0003815604
LEI:
549300RZCKGWRUBPMY22
Country:
Sweden
Address:
Klara Norra Kyrkogata 26, 111 22 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious, rare diseases with significant unmet medical needs. The company's strategy centers on advancing projects through late-stage clinical development to regulatory approval and market launch. Its leading drug candidate, Emcitate, targets MCT8 deficiency, a rare genetic disease characterized by a shortage of thyroid hormones in the brain.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Change in the number of shares and votes in Egetis Therapeutics
English 58.2 KB
2025-10-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Egetis Therapeutics
Swedish 61.4 KB
2025-10-23 08:00
Legal Proceedings Report
Egetis beviljas löpande NDA-granskning av FDA för Emcitate® (tiratricol) basera…
Swedish 90.0 KB
2025-10-23 08:00
Regulatory News Service
Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on …
English 86.3 KB
2025-10-02 23:40
Share Issue/Capital Change
Egetis Therapeutics has successfully carried out a directed share issue amounti…
English 82.9 KB
2025-10-02 23:40
Share Issue/Capital Change
Egetis Therapeutics har framgångsrikt genomfört en riktad nyemission uppgående …
Swedish 83.7 KB
2025-10-02 17:31
Share Issue/Capital Change
Egetis Therapeutics intends to carry out a directed share issue of up to 10 per…
English 76.8 KB
2025-10-02 17:31
Share Issue/Capital Change
Egetis Therapeutics avser att genomföra en riktad nyemission av högst 10 procen…
Swedish 78.4 KB
2025-08-21 07:00
Interim Report
Swedish 3.7 MB
2025-08-21 07:00
Interim Report
English 3.4 MB
2025-07-15 08:00
Regulatory News Service
Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 de…
English 75.2 KB
2025-07-15 08:00
Legal Proceedings Report
Egetis erhåller Breakthrough Therapy Designation från FDA för tiratricol för be…
Swedish 71.1 KB
2025-05-16 00:00
Annual Report (ESEF)
Swedish 12.4 MB
2025-05-06 17:59
Post-Annual General Meeting Information
Kommuniké från Egetis Therapeutics årsstämma 2025
Swedish 55.3 KB
2025-05-06 17:59
Post-Annual General Meeting Information
Bulletin from Egetis Therapeutics’ Annual General Meeting 2025
English 52.3 KB

Automate Your Workflow. Get a real-time feed of all Egetis Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Egetis Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Egetis Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-01-09 Yilmaz Mahshid Other Sell 39,753 268,332.75 SEK
2025-01-08 Yilmaz Mahshid Other Sell 98,567 653,499.21 SEK
2025-01-07 Yilmaz Mahshid Other Sell 74,769 507,681.51 SEK
2024-10-07 Nicklas Westerholm Other Buy 10,142 43,103.50 SEK
2024-10-07 Yilmaz Mahshid Other Buy 10,000 42,250.00 SEK
2023-07-07 Henrik Krook Other Buy 33,594 133,704.12 SEK
2023-07-06 Christian Sonesson Other Buy 3,616 14,391.68 SEK
2023-07-06 Christian Sonesson Other Buy 2,000 7,920.00 SEK
2023-07-05 Christian Sonesson Other Buy 1,384 5,452.96 SEK
2023-07-04 Nicklas Westerholm Other Buy 15,350 60,632.50 SEK

Peer Companies

Company Country Ticker View
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea 322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan 4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan 4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea 017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America NBTX
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland NANOFH
NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland NNG

Talk to a Data Expert

Have a question? We'll get back to you promptly.